Stoke Therapeutics heads into its August 7 earnings print as one of the more heavily shorted small-cap biotechs in the RNA medicine space, with positioning that has shifted sharply more bearish over the past month.
Short sellers have been building aggressively. Short interest has climbed to 27.5% of the free float — up 33% in a month and nearly 14% in the last week alone, with the jump concentrated around July 23-24. At roughly 20 days to cover based on official FINRA data, any forced unwind would take time. The ORTEX short score has edged up to 70.6, ranking in the 11th percentile for short score favorability — meaning the stock is more heavily shorted than roughly 89% of comparable names. Yet the borrow market tells a more nuanced story: availability is running at 562%, indicating ample shares remain for new shorts to enter. Cost to borrow has stayed low at around 0.55%, barely moved from a month ago. Bears are piling in, but they are not facing a squeeze dynamic — there is plenty of lending supply.
Options positioning has turned dramatically more defensive, and that is the sharpest signal in the data. The put/call ratio has climbed to 5.13 — double its 20-day average of 2.56 and near the 52-week high of 5.25 reached just a week ago. Put buyers have dominated since late July, a period that coincides almost exactly with the short interest surge. The stock is down 10% over the past month to $29.56, though it has stabilised slightly, gaining about 2.4% in the last session. Peers and fell 2% and 5% respectively on the day, suggesting some sector drag, though STOK has held up relatively better on the week.
The debate centers on zorevunersen, the company's lead RNA candidate for Dravet syndrome. Bulls point to the Phase 3 enrollment milestone and the company's TANGO platform, which targets selective protein up-regulation — a mechanism with potential across multiple rare disease indications. Goldman Sachs initiated coverage with a Buy and a $44 target in mid-July, adding institutional credibility to the bull case. The consensus remains Buy across 12 analysts, with a mean target of $45.82 against a current price near $30 — implying roughly 55% upside if the Street's thesis plays out. Bears counter with the binary nature of Phase 3 outcomes, the likelihood of additional capital raises before profitability, and the potential for share dilution. Wellington Management added 2.36 million shares in the most recent quarter, a notable commitment; Lynx1 Capital trimmed by 641,000 shares over the same period, reflecting divided conviction even among sophisticated holders.
The August 7 print is less an earnings event in the traditional sense and more a clinical and operational update — what the company communicates about trial progress, cash runway, and any early data signals will test whether the 27% short position has correctly anticipated bad news, or is exposed to a sharp unwind.
See the live data behind this article on ORTEX.
Open STOK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
